KYMR Q3 EPS Forecast Cut by Brookline Capital Management

Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) - Research analysts at Brookline Capital Management decreased their Q3 2025 earnings per share (EPS) estimates for Kymera Therapeutics in a research report issued on Wednesday, June 25th. Brookline Capital Management analyst L. Cann now anticipates that the company will earn ($1.03) per share for the quarter, down from their prior forecast of ($0.85). The consensus estimate for Kymera Therapeutics' current full-year earnings is ($2.79) per share. Brookline Capital Management also issued estimates for Kymera Therapeutics' Q4 2025 earnings at ($1.05) EPS, FY2025 earnings at ($3.21) EPS, FY2026 earnings at ($4.72) EPS, FY2027 earnings at ($5.20) EPS, FY2028 earnings at ($6.24) EPS and FY2029 earnings at ($5.61) EPS.

Several other research analysts also recently commented on KYMR. BTIG Research restated a "buy" rating and set a $59.00 price objective on shares of Kymera Therapeutics in a research report on Thursday, June 26th. JPMorgan Chase & Co. lifted their price target on Kymera Therapeutics from $57.00 to $64.00 and gave the company an "overweight" rating in a research note on Tuesday, June 3rd. Guggenheim restated a "buy" rating and set a $60.00 price objective on shares of Kymera Therapeutics in a research report on Tuesday, June 3rd. Bank of America upgraded Kymera Therapeutics from a "neutral" rating to a "buy" rating and set a $51.00 target price on the stock in a research report on Monday, June 2nd. Finally, Stifel Nicolaus initiated coverage on Kymera Therapeutics in a research note on Tuesday, May 20th. They set a "buy" rating and a $55.00 target price for the company. Two investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Kymera Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $59.11.

Kymera Therapeutics Stock Performance

Shares of Kymera Therapeutics stock traded up $0.28 on Monday, reaching $44.81. 240,361 shares of the stock were exchanged, compared to its average volume of 630,954. The firm has a market cap of $2.92 billion, a PE ratio of -14.45 and a beta of 2.18. The firm's 50 day moving average is $38.00 and its 200-day moving average is $35.89. Kymera Therapeutics has a one year low of $19.45 and a one year high of $53.27.

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last issued its quarterly earnings results on Friday, May 9th. The company reported ($0.82) EPS for the quarter, topping analysts' consensus estimates of ($0.92) by $0.10. Kymera Therapeutics had a negative return on equity of 30.11% and a negative net margin of 409.07%. The company had revenue of $22.10 million for the quarter, compared to analysts' expectations of $11.38 million. During the same quarter last year, the business earned ($0.69) earnings per share. Kymera Therapeutics's revenue was up 114.6% on a year-over-year basis.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Wellington Management Group LLP increased its position in shares of Kymera Therapeutics by 13.0% during the first quarter. Wellington Management Group LLP now owns 5,996,873 shares of the company's stock worth $164,134,000 after buying an additional 689,547 shares during the period. Avoro Capital Advisors LLC grew its stake in Kymera Therapeutics by 14.4% during the fourth quarter. Avoro Capital Advisors LLC now owns 5,150,000 shares of the company's stock worth $207,184,000 after purchasing an additional 650,000 shares during the period. Deerfield Management Company L.P. Series C acquired a new stake in shares of Kymera Therapeutics during the 4th quarter worth approximately $23,856,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Kymera Therapeutics by 121.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 896,404 shares of the company's stock valued at $24,535,000 after acquiring an additional 491,737 shares in the last quarter. Finally, Boxer Capital Management LLC acquired a new position in shares of Kymera Therapeutics during the 4th quarter valued at $17,098,000.

Insider Buying and Selling at Kymera Therapeutics

In related news, Director Bros. Advisors Lp Baker acquired 655,500 shares of the business's stock in a transaction that occurred on Monday, June 30th. The shares were bought at an average cost of $44.00 per share, with a total value of $28,842,000.00. Following the completion of the purchase, the director directly owned 6,117,295 shares in the company, valued at $269,160,980. The trade was a 12.00% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link. Also, Director Bvf Partners L. P/Il bought 317,167 shares of Kymera Therapeutics stock in a transaction that occurred on Monday, June 30th. The stock was bought at an average price of $44.00 per share, for a total transaction of $13,955,348.00. Following the completion of the acquisition, the director directly owned 2,798,795 shares of the company's stock, valued at $123,146,980. The trade was a 12.78% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold 48,349 shares of company stock worth $2,334,301 over the last 90 days. Company insiders own 16.01% of the company's stock.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.